Photo via Daily Mail

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist

Read the original at Daily Mail ↗
Cite

Hynds, J. (2026, October 22). World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist. Daily Mail. https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

Dated from the outlet's own feed. Check the original for its byline.

Daily Mail · collected 2026-10-23 · by Joanna Hynds

Quick Summary

Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment, potentially improving survival rates for melanoma patients and possibly extending to other cancers as well.
Written by AI on 2026-10-23, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Moderna and MSD developed intismeran, a personalized mRNA-based vaccine, which when combined with Keytruda (pembrolizumab) reduced the risk of melanoma recurrence or death by 42% in patients two years after surgery. The trial included over 1,100 participants with high-risk melanoma that had been surgically removed. Intismeran targets up to 34 tumor neoantigens specific to each patient's tumor, enhancing the immune system’s ability to fight cancer. Although results are promising and could mark a turning point in personalized cancer treatment, longer-term studies are needed to confirm long-term benefits and impact on overall survival rates. The vaccine is currently experimental and not available on healthcare systems like NHS yet. Similar approaches are being tested for other cancers including kidney, bladder, and lung cancer. The detailed findings were initially scheduled to be presented at the European Society of Medical Oncology Congress but were released ahead of time due to data leaks. Lead researcher Professor Georgina Long from Melanoma Institute Australia described the results as "phenomenal" and potentially transformational for cancer treatment. Independent experts also view the outcome positively, though they emphasize the need for extended follow-up studies to establish definitive benefits in patient longevity.

Written for “mRNA Cancer Vaccine Breakthrough For Melanoma” on 2026-11-02, grounded in this article and the 7 other(s) covering the same event.

Story

📰 mRNA Cancer Vaccine Breakthrough For Melanoma
Health · 8 article(s) covering the same event. Compare every outlet's account →

Compared with similar articles

This article reads unscored and hedges 10% of its claims. Each row says how that neighbour differs.
The Independent
Hedges 0 of 16 claims Outlet record 59/100
TIME
Hedges 3 of 28 claims Outlet record 59/100
ABC News (AU)
Hedges 3 of 34 claims Outlet record 68/100
Evening Standard
Hedges 1 of 25 claims Outlet record 64/100
BBC News
Hedges 2 of 28 claims Outlet record 68/100
Toronto Star
Hedges 3 of 35 claims Outlet record 64/100
CBC News
Hedges 3 of 46 claims Outlet record 74/100
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
10
sentences that state something as happening or true
Uncertain
10%
1 of 10 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
69/100
Daily Mail's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
8
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-23 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Daily Mail · 8837 article(s) · 22 correction(s) detected
Running correction rate · 22 correction(s)

Who wrote this

Joanna Hynds
53 article(s) here · 1 carrying a prediction
🔮 'A grocery shop would cost us at least $150 in Australia, but here we can go to a local market and pay around $15 to $20 and stock up the fridge,' he added.
🔮 'We have not stopped and we will not stop until these people are identified and taken into custody.'
🔮 She claimed the display would not be allowed to continue beyond this year if she didn't go through the council permit process.
🔮 The move follows warnings that Labor’s proposed cuts to working holiday visas could worsen staff shortages and deal a major blow to regional economies.
🔮 Footage has emerged showing the man accused of driving into Independent MP Dr Helen Haines telling police they would have to shoot him during a confrontation four years ago.
🔮 ' Her staff hope to reopen electorate offices in Wangaratta and Wodonga on Thursday, while acknowledging that recovery will take time.
🔮 On May 12, 2023, police searched Warrell Creek at Macksville on the Mid North Coast where they found the man's body hidden inside a large metal cabinet.
🔮 Tesla said all reservations would be cancelled and customers would receive a full refund.
🔮 Dr Howe maintains her rights to academic freedom and free speech are protected by law and has vowed to take her fight to the High Court The university later agreed to the commission's recommendation that she would not need to follow those measures and that no further action would be taken.
🔮 However, on May 15, 2026, the Full Federal Court ruled in Ms Tickle's favour, finding that she had been discriminated against and treated less favourably than a cisgender woman.
Also by Joanna Hynds
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 53 articles by Joanna Hynds →

Topics

Keytruda Melanoma Institute Australia Sydney intismeran the University of Sydney

Subjects

Georgina Long PERSON · 2× Melanoma Institute Australia ORG · 2× Australian NORP · 1× Long PERSON · 1× MSD ORG · 1× Moderna ORG · 1× NSW GPE · 1× Sydney GPE · 1× Westmead Hospital ORG · 1× the University of Sydney ORG · 1×

Narrative

Professor Georgina Long (pictured) led the clinical trial of a world-first cancer vaccine that dramatically reduced the risk of melanoma recurrence or death The trial was conducted across 157 sites worldwide and involved 1,137 patients whose melanoma had been surgically removed but who remained at high risk of the cancer returning.
framing: assertive · carried by 1 article(s) · first seen 2026-10-23
🔮 The landmark findings could pave the way for personalised cancer vaccines to improve survival rates for patients with melanoma and potentially other cancers.

Claims (10 extracted, 1 hedged)

A Sydney scientist is leading a world-first cancer vaccine trial that has dramatically reduced the risk of melanoma returning or patients dying from the disease. asserted
melanoma → lead → disease
The study found the vaccine cut the risk of cancer recurrence or death by 42 per cent compared with patients who received only an immunotherapy drug, pembrolizumab, which is sold under the brand name Keytruda. asserted
which → find → name
The landmark findings could pave the way for personalised cancer vaccines to improve survival rates for patients with melanoma and potentially other cancers. uncertain
vaccines → pave → melanoma
'These results show that patients with earlier-stage melanoma can be treated after surgery in a fundamentally new way,' Professor Long said. ' asserted
Long → show → way
Just as email transformed how we communicate, individualised neoantigen therapy has the potential to transform how we treat cancer. asserted
we → transform → cancer
The vaccine, known as intismeran, is being jointly developed by pharmaceutical companies Moderna and MSD. asserted
vaccine → know → companies
Intismeran is an individualised messenger RNA (mRNA) cancer vaccine designed specifically for each patient, based on the unique genetic characteristics of their tumour. asserted
Intismeran → design → tumour
Professor Georgina Long (pictured) led the clinical trial of a world-first cancer vaccine that dramatically reduced the risk of melanoma recurrence or death The trial was conducted across 157 sites worldwide and involved 1,137 patients whose melanoma had been surgically removed but who remained at high risk of the cancer returning. asserted
cancer → picture → risk
None of the participants had previously received drug treatment for their cancer. asserted
None → receive → cancer
The trial ran across a host of Australian sites, including Melanoma Institute Australia, Westmead Hospital in NSW, Princess Alexandra Hospital in Queensland, and the Paula Fox Melanoma and Cancer Centre and Peter MacCallum Cancer Centre in Victoria. asserted
trial → run → Victoria
💬Give feedback
🕘History 🎫Support